Skip to main content
. 2025 Jun 11;13(6):628. doi: 10.3390/vaccines13060628
COVID-19 coronavirus disease 2019
UTR untranslated region
HAI hemagglutination inhibition
RBD receptor binding domain
IVT in vitro transcription
LNP lipid nanoparticle
RTU LNP ready-to-use lipid nanoparticle
GMT geometric mean titer
ccCVVs cell culture-based candidate vaccine viruses
NIBSC National Institute for Biological Standards and Control
CDC Centers for Disease Control and Prevention
RLU relative luminescence units
TCID50 Tissue Culture Infectious Dose 50%